(Stroke. 2000;31:1974.)
© 2000 American Heart Association, Inc.
Original Contributions |
, MDFrom the Department of Neurology, Faculty of Medicine, and Institute of Neurological Sciences and Psychiatry, Hacettepe University, Ankara, Turkey.
Correspondence to Turgay Dalkara, Department of Neurology, Hacettepe University Hospitals, Ankara, 06100, Turkey. E-mail dalkara{at}tr-net.net.tr
| Abstract |
|---|
|
|
|---|
MethodsWe have examined the role of NO generation and peroxynitrite formation on reperfusion injury in a mouse model of middle cerebral artery occlusion (2 hours) and reperfusion (22 hours). The infarct volume was assessed by 2,3,5-triphenyl tetrazolium chloride staining; blood-brain barrier permeability was evaluated by Evans blue extravasation. Nitrotyrosine formation and matrix metalloproteinase-9 expression were detected by immunohistochemistry.
ResultsInfarct volume was significantly decreased (47%) in
animals treated with the nonselective nitric oxide synthase (NOS)
inhibitor N
-nitro-L-arginine
(L-NA) at reperfusion. The specific inhibitor of neuronal
NOS, 7-nitroindazole (7-NI), given at reperfusion, showed no
protection, although preischemic treatment with 7-NI
decreased infarct volume by 40%. Interestingly, prereperfusion
administration of both NOS inhibitors decreased tyrosine
nitration (a marker of peroxynitrite toxicity) in the ischemic
area. L-NA treatment also significantly reduced vascular damage, as
indicated by decreased Evans blue extravasation and matrix
metalloproteinase-9 expression.
ConclusionsThese data support the hypothesis that in addition to the detrimental action of NO formed by neuronal NOS during ischemia, NO generation at reperfusion plays a significant role in reperfusion injury, possibly through peroxynitrite formation. Contrary to L-NA, failure of 7-NI to protect against reperfusion injury suggests that the source of NO is the cerebrovascular compartment.
Key Words: cerebral ischemia, focal matrix metalloproteinases nitrates nitric oxide reperfusion injury
| Introduction |
|---|
|
|
|---|
An increased production of nitric oxide (NO) in the brain has been demonstrated during ischemia.7 8 9 10 11 Available evidence suggests that both neuronal and endothelial isoforms generate NO at the beginning of ischemia until the constitutive nitric oxide synthases (NOS) are inactivated.8 10 11 12 13 Al- though endothelial NO production is believed to positively affect the outcome of ischemia by improving ischemic blood flow, overproduction of NO in the brain parenchyma has been demonstrated to contribute to tissue damage.9 14 15 NO may be toxic by several mechanisms; however, formation of peroxynitrite after a reaction between NO and superoxide appears to be one of the major pathways leading to cell death.16 17 18 Constitutive NOS is reactivated on reperfusion, as indicated by resumption of NO generation.10 11 A concomitant surge in superoxide production may lead to peroxynitrite formation.5 16 Peroxynitrite is a powerful oxidant with a relatively long half-life and is more toxic than NO and superoxide individually.16 Hence, peroxynitrite has been proposed as one of the putative mediators of reperfusion injury.19 20
We have tested this hypothesis in a mouse model of transient
ischemia by inhibiting NO synthesis just before reperfusion
after 2 hours of middle cerebral artery (MCA) occlusion. Our findings
indicate that the nonselective NOS inhibitor
N
-nitro-L-arginine
(L-NA) but not a selective inhibitor of neuronal NOS
(nNOS), 7-nitroindazole (7-NI), decreases infarct volume and Evans blue
extravasation by
50%. In line with these data, L-NA diminished
tyrosine nitration in cerebral vessels and brain tissue, possibly by
inhibiting peroxynitrite formation.
| Materials and Methods |
|---|
|
|
|---|
A total of 65 mice were studied. Thirty-six mice were subjected to 2 hours of proximal MCA occlusion and 22 hours of reperfusion and were studied in 6 groups: (1) 7 mice were injected intraperitoneally with L-NA 15 minutes before reperfusion; (2) 7-NI (50 mg/kg IP, dissolved in peanut oil) was given 30 minutes before ischemia (n=4) or (3) 30 minutes before reperfusion (n=6); (4) 4 mice were given 7-NI (50 mg/kg) 30 minutes before ischemia and L-NA (1 mg/kg) 15 minutes before reperfusion; (5) 5 mice were infused with phenylephrine (30 to 60 µg/h IV) for 30 minutes after reperfusion to increase arterial blood pressure to values comparable to those recorded in L-NA-treated groups; and (6) 10 mice received saline intraperitoneally 15 minutes before reperfusion.
Another set of 11 mice were subjected to 2 hours of ischemia and 5 hours of reperfusion for nitrotyrosine immunohistochemistry. For matrix metalloproteinase immunohistochemistry, 7 mice, and to evaluate Evans blue extravasation, 11 mice were subjected to 2 hours of ischemia and 22 hours of reperfusion.
MCA Occlusion
Proximal occlusion of the right MCA was performed with the use
of a nylon filament, as described previously.9 Briefly,
the right common carotid artery and external carotid artery were
ligated by a 5-0 silk suture after a midline incision. A nylon filament
(8/0) was inserted into the common carotid artery through a small
incision proximal to the bifurcation and advanced in the internal
carotid artery up to the origin of MCA (10 mm from the
bifurcation). The distal 3 mm of 8/0 filament was coated with
silicon.
A flexible probe (PF-318 of PeriFlux PF 2B, Perimed) was placed over the skull (2 mm posterior, 6 mm lateral to the bregma), away from large pial vessels to monitor the regional cerebral blood flow (rCBF) by laser Doppler flowmetry. After obtaining a stable 10-minute epoch of preischemic rCBF, the MCA was occluded and rCBF was continuously monitored during ischemia (2 hours) and the first 20 to 40 minutes of reperfusion. Reperfusion was accomplished by pulling the filament back.
Evaluation of Ischemic Area by TTC Staining
The ischemic area was evaluated by TTC staining.
Briefly, after an overdose of pentobarbital, mice were killed by
decapitation after 2 hours of ischemia and 22 hours of
reperfusion. The brains were quickly removed and placed in ice-cold
saline for 5 minutes and then cut into 2-mm coronal slices. Sections
were incubated in TTC-containing saline solution (2%, Sigma Chemical
Co) for 20 minutes and in 10% formalin overnight. The infarction area,
outlined in white, was measured by an image-analysis software
(NIH Image 1.59) on the posterior surface of each section, and
infarction volume was calculated by summing the infarct volume of
sequential 2-mm-thick sections. Mice showing hippocampal involvement
caused by circle of Willis anomalies21 were excluded from
the study.
Neurological Evaluation
Twenty-two hours after recirculation, neurological deficits were
assessed by an observer blinded to the identity of treatment and scored
as described previously9 : 0, no observable neurological
deficits (normal); 1, failure to extend left forepaw on lifting the
whole body by the tail (mild); 2, circling to the contralateral side
(moderate); 3, leaning to the contralateral side at rest or no
spontaneous motor activity (severe).
Evans Blue Extravasation
Blood-brain barrier permeability was assessed by measuring Evans
blue extravasation. Evans blue (Sigma, 0.1 mL of 4% solution) was
injected into the tail vein at reperfusion.22 Mice were
transcardially perfused with 100 mL of heparinized saline solution (10
IU/mL) 22 hours after reperfusion. Brains were removed and hemispheres
were separated. Each hemisphere was well homogenized in 1
mL of 0.1 mol/L PBS and then centrifuged at 1000g
for 15 minutes; 0.7 mL of 100% trichloroacetic acid was added into 0.7
mL of supernatant. The mixture was incubated at +4°C for 18 hours and
then centrifuged at 1000g for 30 minutes. The amount
of Evans blue in supernatant was measured spectrophotometrically at
610-nm wavelength by comparison with readings obtained from standard
solutions. Results were expressed as micrograms per hemisphere.
Immunohistochemistry
After 2 hours of ischemia and 5 hours of reperfusion,
mice (4 treated with L-NA, 3 with 7-NI, and 4 with vehicle at
reperfusion) were perfused transcardially with 4%
paraformaldehyde solution. Brains were removed and kept
in paraformaldehyde for 48 hours and were subsequently
embedded in paraffin. After 4-µm-thick slices were obtained, they
were deparaffinized at 56°C overnight and hydrated in xylol and
graded alcohol solutions. Sections were stained with anti-nitrotyrosine
antibody (1/100 monoclonal, Upstate Biotechnology, Inc) by the
avidin-biotin method.23 To establish the specificity of
antibody binding, 1 set of the tissue sections was incubated with
antibody mixed with 15 mmol/L nitrotyrosine solution (dissolved in
PBS and adjusted to pH 7.6) for 6 hours at room temperature.
After 2 hours of ischemia and 22 hours of reperfusion, 4-µm-thick paraffin sections were prepared as above from 7 mice (3 treated with L-NA and 4 with vehicle) and were stained with anti-matrix metalloproteinase-9 (MMP-9, Calbiochem) antibody (1/50) by the avidin-biotin method, as described before.24 Primary antibody was omitted to test the specificity of staining. Diaminobenzidine was used as chromogen and hematoxylin as counterstain for both antibodies.
Brain slices were evaluated for nitrotyrosine or MMP-9 staining by an observer blinded to the identity of treatment. Immunolabeled vessels in the ischemic area were counted manually over 100 contiguous complete microscopic fields (magnification x400) on sections taken 2.5 mm posterior of the frontal pole and passing through the anterior commissure.
Statistics
Mean values of arterial blood gases, pH, blood
pressure, rCBF values, infarct volume, neurological examination scores,
and number of vessels immunolabeled with nitrotyrosine antibody were
compared by means of the Kruskal-Wallis test followed by the
Mann-Whitney U test. The number of vessels immunolabeled
with antiMMP-9 antibody and amount of Evans blue extravasation
between the vehicle and L-NAtreated groups were compared by means of
the Mann-Whitney U test. Values of P<0.05 were
considered to be significant. Mean values in the text are given with
their standard deviations.
| Results |
|---|
|
|
|---|
|
Infarct Volume
L-NA treatment before reperfusion decreased the infarct volume by
47% (Figure 1A
). Two-hour MCA occlusion
followed by 22 hours of reperfusion caused an infarct of 75±16
mm3 in vehicle-treated mice (n=10).
Administration of 1 mg/kg of L-NA 15 minutes before reperfusion
decreased the infarct volume to 40±15 mm3
(n=7). 7-NI (50 mg/kg) showed no protection when administered 30
minutes before reperfusion (82±22 mm3,
n=6), although it reduced the infarct volume to 45±4
mm3 when given 30 minutes before ischemia
(n=4). Combining 7-NI (50 mg/kg) pretreatment with L-NA (1 mg/kg)
administration before reperfusion (n=4) did not provide any further
protection compared with L-NA treatment alone and reduced the infarct
volume to 40±9 mm3. A combined
administration of 7-NI and L-NA 30 and 15 minutes (respectively) before
reperfusion caused a high mortality rate during or shortly after
surgery; therefore, the effect of this approach on reperfusion injury
could not be tested. To test the effect of L-NAinduced modest blood
pressure increase at reperfusion on infarct development,
phenylephrine was infused intravenously
starting at the beginning of reperfusion. Since mice started waking up
from anesthesia after 30 minutes of reperfusion, the
arterial blood pressure increased to values >100
mm Hg in all groups irrespective of phenylephrine, L-NA,
or vehicle administration; hence, phenylephrine infusion
was given for only 30 minutes. The infusion rate (30 to 60 µg/h) was
adjusted so that phenylephrine increased the mean
arterial pressure to values comparable to those
recorded from L-NAtreated animals with a similar time course
(Table
). However, phenylephrine infusion showed no
protection (85±19 mm3, n=5).
|
Neurological Evaluation
Mean neurological disability scores determined 22 hours after
reperfusion paralleled the changes in infarct volume in all groups
(Figure 1B
). Treatment with L-NA before reperfusion and with
7-NI before ischemia significantly reduced disability scores
compared with vehicle. The combined administration of 7-NI and L-NA led
to a similar reduction in neurological dysfunction to L-NA treatment
alone. Phenylephrine infusion provided no reduction in
disability scores.
Evans Blue Extravasation
Evans blue extravasation 22 hours after reperfusion was 1.00±0.16
µg Evans blue per hemisphere in the vehicle-treated group (n=5). L-NA
treatment before reperfusion led to a 50% reduction in extravasation
(0.50±0.08 µg per hemisphere, n=6, Figure 2
).
|
Immunohistochemistry
Parenchyma and vessels in the ischemic territory were
labeled with anti-nitrotyrosine antibody (Figure 3
, A through F). This staining was
considered to be specific because it was abolished by incubating the
antibody with 3-nitrotyrosine or by omitting the antibody from the
staining procedure, and brain sections from nNOS knockout mice
subjected to permanent MCA occlusion for 6 hours (kindly provided by Dr
M.A. Moskowitz of Massachusetts General Hospital, Boston) showed no
immunolabeling. In preliminary experiments, we found that the intensity
of ischemic changes and anti-nitrotyrosine staining were
variable 1 hour after reperfusion. A dense staining was observed 5
hours after reperfusion, which declined by 22 hours. Therefore, we
continued the study by comparing immunolabeling between groups 5 hours
after reperfusion after 2 hours of ischemia.
|
At 5 hours, the intensity of ischemic changes were variable
and patchy within the MCA territory. Nitrotyrosine staining closely
paralleled the intensity of tissue damage, and intense labeling was
prominent in the core region. Presumably glial cells (identified by
light microscopic criteria) were negative, whereas neuronal cell bodies
and neuropil were labeled (Figure 3
, A through F).
Immunolabeling of microvessels was more prominent than staining of
neuropil and covered the whole MCA area, being more intense in the core
(Figure 3
, A and B). Administration of both L-NA (Figure 3
, C and D) and 7-NI (Figure 3
, E and F) before
reperfusion significantly but incompletely decreased nitrotyrosine
immunolabeling of parenchyma and microvessels. Since quantification of
parenchymal staining was less reliable compared with counting labeled
microvessels, we compared the number immunolabeled microvessels in the
ischemic hemisphere between groups. The number of
immunopositive vessels was significantly less in L-NAtreated mice
(644±182 per section, n=4) compared with the vehicle-treated group
(1920±1040 per section, n=4). 7-NI treatment before reperfusion also
significantly decreased the number of
anti-nitrotyrosineimmunopositive vessels (691±107 per section, n=3)
(Figure 4A
). We normalized the number of
vessels for the area of ischemic region because the decrease in
ischemic area after NOS inhibitors may contribute
to the reduction in the number of immunolabeled vessels. Differences
between groups were sustained after normalization: The number of
vessels (in per mm2 of ischemic
area) was 155±82 for vehicle (n=4), 71±27 for L-NA (n=4), and 81±30
for 7-NI treatment groups (n=3).
|
Twenty-two hours after reperfusion, antiMMP-9 antibody positively
labeled the parenchyma and vessels in the ischemic territory
(Figure 3
, G and H). The specificity of staining was tested by
omitting the antibody from the staining procedure. The number of
immunolabeled vessels was decreased in the L-NAtreated group
(561±64, n=3) compared with the saline-treated group (1050±314, n=4)
(Figure 4B
).
| Discussion |
|---|
|
|
|---|
One possibility is that 7-NI may have failed because of an insufficient inhibition of neuronal NO synthesis. 7-NI (25 to 60 mg/kg IP) has been shown to inhibit brain NOS activity rapidly (reaching a maximum in 15 to 30 minutes) but incompletely (47% to 65%) in the mouse and rat.14 36 37 However, intraperitoneal administration of 1 mg/kg L-NA also inhibits brain NOS activity partially (maximum 74%).38 Hence, the major difference between the 2 inhibitors at the time of reperfusion appears to be the inhibition endothelial NOS (eNOS) by L-NA but not 7-NI, as also indicated by changes in blood pressure (see References 14 36 37 ).
We have also excluded the possibility that the L-NAinduced blood pressure increase may have provided a better reperfusion and a more favorable outcome by showing that a comparable increase in blood pressure obtained by phenylephrine infusion had no neuroprotective effect. Although statistically not significantly different than rCBF values in other groups, slightly lower rCBF values during reperfusion in the 7-NIprereperfusion treatment group may be thought to have masked any beneficial effect of 7-NI. However, the phenylephrine study indicates that moderate hemodynamic changes during reperfusion after 2 hours of MCA occlusion are not so critical as they are during ischemia. In fact, the group given combined 7-NI and L-NA treatments had higher blood pressure and rCBF values during reperfusion, yet displayed no additional benefit that could be attributed to 7-NI. Taken together, we can conclude that the protective action of L-NA is unlikely to be due to pharmacokinetic or hemodynamic factors but rather points to the importance of inhibition of vascular sources of NO. Recently, Wei et al,39 by using nNOS and eNOS knockout mice, showed that eNOS accounted for half of the NO surge seen during reperfusion after global ischemia. If the eNOS is comparably overactive during reperfusion after MCA occlusion, L-NA will clearly provide a superior protection compared with 7-NI by blocking eNOS as well.
Several laboratories that used various chemical detection methods have demonstrated that brain NO level increases at the beginning of focal ischemia.7 8 9 10 11 15 This increase is not sustained during the course of ischemia, possibly because of inactivation of constitutive NOS.8 12 13 However, NO synthesis resumes on reperfusion.10 11 Kumura et al40 detected a surge in hemoglobin-NO, nitrite, and nitrate levels in jugular blood during reperfusion after 2-hour MCA occlusion. An excessive superoxide production was also reported after reperfusion.5 Administration of superoxide dismutase (SOD) further increased the hemoglobin-NO signal at reperfusion in the study by Kumura and colleagues,40 indicating that some of the NO produced was converted to peroxynitrite by reacting with superoxide during reperfusion. In line with these findings, a second surge of nitrotyrosine formation was detected in the penumbral cortex after reperfusion.20 Although current methods have shortcomings to unequivocally establish the compartment that peroxynitrite formation takes place, the study by Kumura and colleagues40 indicates that the intimate colocalization between superoxide and NO generation required for formation of peroxynitrite is realized in the vascular compartment.
Supporting the above view, we have seen an intense nitrotyrosine immunostaining in vascular walls, including the endothelium within the ischemic area. Neurons and neuropil were also densely stained, and 7-NI significantly decreased vascular as well as parenchymal staining, suggesting that nNOS in neurons and perivascular nerves contributed to peroxynitrite formation and nitration of tyrosine residues. It is surprising that 7-NI was not protective against reperfusion injury, although it decreased nitrotyrosine (hence peroxynitrite) formation to an extent comparable to L-NA administration. Although these findings suggest a nonperoxynitrite-mediated, yet unidentified NO-related mechanism, the possibility that staining of critical targets may have been masked by labeling of free and other protein-bound nitrotyrosine should be considered. It is likely that peroxynitrite generation within the vascular endothelium may specifically target some critical molecules to disrupt vascular integrity and increase microvascular permeability.41 42 Compartmentalization of these target molecules within the vascular wall or localization of detoxification mechanisms (eg, SOD) or local tissue factors (eg, pH) may hinder nNOS-generated peroxynitrite to reach these vascular targets, although peroxynitrite has the ability to diffuse and damage distant molecules.16 43 Absence of immunoreactivity in some cells (presumably glia) next to the intensely stained neurons and microvessels points to the importance of local cellular factors and rate of nitrotyrosine removal in determining the outcome of peroxynitrite-induced injury. Astrocytes have high SOD levels, whereas neurons as well as vascular cells have been reported to express NADPH oxidase, which may be a significant source of oxidative stress.4 44 Removal of nitrotyrosine appears to be particularly important because more peroxynitrite is generated in the penumbra, as detected by HPLC,16 20 43 but nitration is possibly quickly restored and escapes detection by immunohistochemistry, whereas nitrotyrosine remains bound to proteins in the core. Complex and pH-dependent chemistry between peroxynitrite, NO, and nitrite may also contribute to this discrepancy; however, these reactions are yet not well characterized in vivo to correctly anticipate the net outcome.43
It is tempting to speculate that eNOS may generate both NO and superoxide as the result of ischemia-induced L-arginine or tetrahydrobiopterin depletion,15 45 46 and this may provide the optimum colocalization for a high throughput peroxynitrite production within the endothelium that (perhaps together with an additional source coming from the leukocytes adhered to endothelium) will especially damage vascular targets. In support of this view, L-NA not only reduced the infarct volume but also decreased blood-brain barrier leakage as detected by Evans blue extravasation. A reduced MMP-9 expression also indicates better preserved vascular integrity in L-NAtreated animals. The vascular basement membrane plays a critical role in maintaining integrity of the blood-brain barrier by providing structural support to the endothelial wall. Recently, an increase in activity of matrix metalloproteinases (a group of enzymes that degrade proteins of the extracellular matrix) and a decrease in extracellular matrix molecules such as type IV collagen, laminin, and fibronectin after ischemia/reperfusion have been demonstrated.3 24 In these studies, MMP-9 was detected in the ischemic tissue within 2 to 6 hours after ischemia and was markedly expressed at 24 hours.24 47
Apart from its toxicity by leading to peroxynitrite formation, NO synthesized in the endothelium may positively affect the outcome by decreasing platelet and white blood cell clogging during reperfusion.34 L-NA has been reported to have a U-shaped effect when administered during reperfusion.29 The unfavorable action seen with high doses of L-NA may be due to profound inhibition of eNOS, promoting cellular adhesion. In fact, administration of NO donors during reperfusion was reported to decrease tissue damage after peripheral arterial occlusion.35 The dose we used caused a modest increase in blood pressure, indicating that L-NA only partially inhibited eNOS. The partial inhibition of eNOS therefore may provide the optimum benefit by inhibiting peroxynitrite formation (or yet an unidentified NO-related mechanism) without significantly increasing intravascular clogging.
In conclusion, these data support the hypothesis that NO generation at reperfusion plays an important role in reperfusion injury, possibly by peroxynitrite formation. Contrary to L-NA, failure of 7-NI to protect against reperfusion injury suggests that the source of NO is the vascular compartment.
| Acknowledgments |
|---|
lu, MD, for their help with
spectrophotometric analysis and photomicrographs,
respectively. Received November 10, 1999; revision received May 9, 2000; accepted May 9, 2000.
| References |
|---|
|
|
|---|
2. Aronowski J, Strong R, Grotta JC. Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab.. 1997;17:10481056.[Medline] [Order article via Infotrieve]
3.
Hamann GF, Okada Y, Fitridge Y, del Zoppo GJ.
Microvascular basal lamina antigens disappear during cerebral
ischemia and reperfusion. Stroke. 1995;26:21202126.
4.
Chan PH. Role of oxidants in ischemic brain
damage. Stroke. 1996;27:11241129.
5. Peters O, Back T, Lindauer U, Busch C, Megow D, Dreier J, Dirnagl U. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab. 1998;18:196205.[Medline] [Order article via Infotrieve]
6. Hall ED. Antioxidant pharmacotherapy. In: Ginsberg M, Bogousslavsky J, eds. Cerebrovascular Disease: Pathophysiology, Diagnosis and Management. Boston, Mass: Blackwell Science; 1997:710720.
7. Tominaga T, Sato S, Ohnishi T, Ohnishi ST. Potentiation of nitric oxide formation following bilateral carotid occlusion and focal cerebral ischemia in the rat: in vivo detection of the nitric oxide radical by electron paramagnetic resonance spin trapping. Brain Res. 1993;614:342346.[Medline] [Order article via Infotrieve]
8.
Kader A, Frazzini VI, Solomon RA, Trifiletti RR.
Nitric oxide production during focal cerebral ischemia
in rats. Stroke. 1993;24:17091716.
9.
Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC,
Moskowitz MA. Effects of cerebral ischemia in mice deficient in
neuronal nitric oxide synthase. Science. 1994;265:18831885.
10. Zhang ZG, Chopp M, Bailey F, Malinski T. Nitric oxide changes in the rat brain after transient middle cerebral artery occlusion. J Neurol Sci. 1995;128:2227.[Medline] [Order article via Infotrieve]
11. Ohta K, Graf R, Rosner G, Heiss W-D. Profiles of cortical tissue depolarization in cat focal cerebral ischemia in relation to calcium ion homeostasis and nitric oxide production. J Cereb Blood Flow Metab. 1997;17:11701181.[Medline] [Order article via Infotrieve]
12. Grandati M, Verrecchia C, Revaud ML, Allix M, Boulu RG, Plotkine M. Calcium-independent NO-synthase activity and nitrites/nitrates production in transient focal cerebral ischaemia in mice. Br J Pharmacol. 1997;122:625630.[Medline] [Order article via Infotrieve]
13. Sporer B, Martens KH, Koedel U, Haberl RL. L-arginine-induced regional cerebral blood flow increase is abolished after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab.. 1997;17:10741080.[Medline] [Order article via Infotrieve]
14. Yoshida T, Limmroth V, Irikura K, Moskowitz MA. The NOS inhibitor, 7-nitroindazole, decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. J Cereb Blood Flow Metab. 1994;14:924929.[Medline] [Order article via Infotrieve]
15. Dalkara T, Endres M, Moskowitz MA. Mechanisms of NO neurotoxicity. In: Mize RR, Dawson TM, Dawson VL, Friedlander MJ, eds. Prog Brain Res.. 1998;118:231239.[Medline] [Order article via Infotrieve]
16. Beckman JS. Interactions of oxidants, nitric oxide, and antioxidant defenses in cerebral ischemia and injury. In: Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease. Boston, Mass: Blackwell Science; 1998:455470.
17.
Eliasson MJL, Huang Z, Ferrante RJ, Sasamata M,
Molliver ME, Snyder SH, Moskowitz MA. Neuronal nitric oxide synthase
activation and peroxynitrite formation in ischemic stroke
linked to neural damage. J Neurosci. 1999;19:59105918.
18. Forman LJ, Liu P, Nagele RG, Yin K, Wong PY. Augmentation of nitric oxide, superoxide, and peroxynitrite production during cerebral ischemia and reperfusion in the rat. Neurochem Res. 1998;23:141148.[Medline] [Order article via Infotrieve]
19. Takizawa S, Fukuyama N, Hirabayashi H, Nakazawa H, Shinohara Y. Dynamics of nitrotyrosine formation and decay in rat brain during focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab. 1999;19:667672.[Medline] [Order article via Infotrieve]
20. Fukuyama N, Takizawa S, Ishida H, Hoshiai K, Shinohara Y, Nakazawa H. Peroxynitrite formation in focal cerebral ischemia-reperfusion in rats occurs predominantly in peri-infarct region. J Cereb Blood Flow Metab. 1998;18:123129.[Medline] [Order article via Infotrieve]
21. Özdemir YG, Bolay H, Erdem E, Dalkara T. Occlusion of the MCA by an intraluminal filament may cause disturbances in the hippocampal blood flow due to anomalies of circle of Willis and filament thickness. Brain Res. 1999;822:260264.[Medline] [Order article via Infotrieve]
22.
Kondo T, Reaume AG, Huang T-T, Carlson E, Murakami K,
Chen SF, Hoffman EK, Scott RW, Epstein CJ, Chan PH. Reduction of
CuZn-Superoxide dismutase activity exacerbates neuronal cell injury and
edema formation after transient focal cerebral ischemia.
J Neurosci. 1997;17:41804189.
23. Beckman JS, Ye YZ, Anderson P, Chen J, Accavitti MA, Tarpey MM, White CR. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe-Seyler. 1994;375:8188.[Medline] [Order article via Infotrieve]
24. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin J-P, Kawase M, Massengale J, Chan PH. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab. 1999;19:10201028.[Medline] [Order article via Infotrieve]
25. Nowicki JP, Duval D, Poignet H, Scatton B. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur J Pharmacol. 1991;204:239240.
26.
Ashwal S, Cole DJ, Osborne TN, Pearce WJ. Dual effects
of L-NAME during transient focal cerebral ischemia in
spontaneously hypertensive rats. Am J Physiol. 1994;267:H276H284.
27. Margaill I, Allix M, Boulu RG, Plotkine M. Dose- and time-dependence of L-NAME neuroprotection in transient focal cerebral ischaemia in rats. Br J Pharmacol. 1997;120:160163.[Medline] [Order article via Infotrieve]
28. Matsui T, Nagafuji T, Mori T, Asano T. N-omega-nitro-L-arginine attenuates early ischemic neuronal damage of prolonged focal cerebral ischemia and recirculation in rats. Neurol Res. 1997;19:192203.[Medline] [Order article via Infotrieve]
29. Spinnewyn B, Cornet S, Auguet M, Chabrier P-E. Synergistic protective effects of antioxidant and nitric oxide synthase inhibitor in transient focal ischemia. J Cereb Blood Flow Metab.. 1999;19:139143.[Medline] [Order article via Infotrieve]
30. Escott KJ, Beech JS, Haga KK, Williams SC, Meldrum BS, Bath PM. Cerebroprotective effect of the nitric oxide synthase inhibitors, 1-(2-trifluoromethylphenyl) imidazole and 7-nitro indazole, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1998;18:281287.[Medline] [Order article via Infotrieve]
31. Zhang ZG, Reif D, MacDonald J, Tang WX, Kamp DK, Gentile RJ, Shakespeare WC, Murray RJ, Chopp M. ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 1996;16:599604.[Medline] [Order article via Infotrieve]
32. Iadecola C, Zhang F, Xu S, Casey R, Ross ME. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab. 1995;15:378384.[Medline] [Order article via Infotrieve]
33. Yoshida T, Waeber C, Huang Z, Moskowitz MA. Induction of nitric oxide synthase activity in rodent brain following middle cerebral artery occlusion. Neurosci Lett. 1995;194:214218.[Medline] [Order article via Infotrieve]
34.
Niu XF, Smith CW, Kubes P. Intracellular oxidative
stress induced by nitric oxide synthesis inhibition increases
endothelial cell adhesion to neutrophils. Circ
Res. 1994;74:11331140.
35. Johnson D, Freischlag JA, Lesniak R, Kelly H, Mudaliar JH, Cambria RA, Seabrook MD, Towne JB. Endothelial damage due to ischemia and reperfusion is prevented with SIN-1. Cardiovasc Surg. 1998;6:527532.[Medline] [Order article via Infotrieve]
36. Moore PK, Wallace P, Gaffen Z, Hart SL, Babbedge RC. Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinociceptive and cardiovascular effects. Br J Pharmacol. 1993;110:219224.[Medline] [Order article via Infotrieve]
37. Stagliano NE, Dietrich WD, Prado R, Green EJ, Busto R. The role of nitric oxide in the pathophysiology of thromboembolic stroke in the rat. Brain Res. 1997;6:759:3240.
38. Carreau A, Duval D, Poignet H, Scatton B, Vige X, Nowicki JP. Neuroprotective efficacy of N omega-nitro-L-arginine after focal cerebral ischemia in the mouse and inhibition of cortical nitric oxide synthase. Eur J Pharmacol. 1994;256:241249.[Medline] [Order article via Infotrieve]
39. Wei G, Dawson VL, Zweier JL. Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. Biochim Biophys Acta. 1999;1455:2334.[Medline] [Order article via Infotrieve]
40.
Kumura E, Yoshimine T, Iwatsuki K-I, Yamanaka K, Tanaka
S, Hayakawa T, Shiga T, Kosaka H. Generation of nitric oxide and
superoxide during reperfusion after focal cerebral ischemia in
rats. Am J Physiol. 1996;270:C748C752.
41. Greenacre S, Ridger V, Wilsoncroft P, Brain SD. Peroxynitrite: a mediator of increased microvascular permeability. Clin Exp Pharmacol Physiol. 1997;24:880882.[Medline] [Order article via Infotrieve]
42.
Gobbel GT, Chan TYY, Chan PH. Nitric oxide and
superoxide-mediated toxicity in cerebral endothelial
cells. J Pharmacol Exp Ther. 1997;282:16001607.
43. Crow JP, Spruell C, Chen J, Gunn C, Ischiropoulos H, Tsai M, Smith CD, Radi R, Koppenol WH, Beckman JS. On the pH-dependent yield of hydroxyl radical products from peroxynitrite. Free Radic Biol Med. 1994;16:331338.[Medline] [Order article via Infotrieve]
44. Tammariello SP, Quinn MT, Estus S. NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. J Neurosci.. 2000;20:RC53:15.
45.
Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL.
Nitric oxide generates superoxide and nitric oxide in arginine-depleted
cells leading to peroxynitrite-mediated cellular injury. Proc
Natl Acad Sci U S A. 1996;93:67706774.
46. Milstein S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun. 1999;263:681684.[Medline] [Order article via Infotrieve]
47. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular diseases. J Cereb Blood Flow Metab. 1998;18:11631172.[Medline] [Order article via Infotrieve]
Department of Anesthesiology University of Alabama at Birmingham
| Introduction |
|---|
|
|
|---|
The pharmacological evidence using 7-NI must be carefully interpreted, because 7-NI is a potent inhibitor of eNOS in vitro. The apparent selectivity for nNOS in vivo may result from the metabolism of the purine-based 7-NI by xanthine dehydrogenase, which is enriched in brain endothelium.R4 Alternatively, export of 7-NI by purine transporters may limit the intracellular accumulation in endothelium.R4 However, a role of NO-dependent injury to brain microvessels was further supported in the present study by observation of increased nitration of tyrosine in the majority of cerebral microvessels in the ischemic territory. This tyrosine nitration was found to increase several hours after reperfusion had been initiated. Nitric oxide itself does not nitrate proteins but can form the much stronger oxidant peroxynitrite by a diffusion-limited reaction with superoxide. Although other reactive nitrogen species can contribute to a fraction of nitrotyrosine formation in vivo, peroxynitrite remains the most efficient source of tyrosine nitration in proteins in biological systems.R5 R6
Immunoprecipitation of proteins with nitrotyrosine antibodies has already identified several targets that could be important in the disruption of cerebrovascular function. Manganese SOD is the major enzymatic scavenger of superoxide in mitochondria and is readily nitrated and inactivated by peroxynitrite in vivo.R7 R8 The sarcoplasmic calcium ATPase found in vascular smooth muscle is inactivated by nitration and has major effects in the control of muscle contractility. Prostacyclin synthase is rapidly inactivated by submicromolar concentrations of peroxynitrite in endothelium.R9 R10 R11 After exposure to peroxynitrite, prostacyclin synthase produces thromboxane-like intermediates that promote vasoconstriction and platelet aggregation.R12 R13 Furthermore, peroxynitrite appears to be the physiological peroxide necessary to activate cyclooxygenase.R14 Consequently, a sustained production of peroxynitrite in the vasculature may strongly promote thromboxane synthesis, disrupt calcium handling to affect contractile strength, and injure mitochondria necessary to maintain the integrity of the blood-brain barrier. These actions would likely promote cerebral injury after stroke.
The narrow time window for successful TPA therapy has greatly limited its success in treating stroke. However, we have only just begun to appreciate the complex secondary effects of oxidative damage induced in the brain microcirculation after cerebral ischemia. The brain endothelium offers the most readily accessible target for therapeutic intervention in the treatment of stroke. Based on the time course of tyrosine nitration reported in the present study, agents to reduce oxidative damage in the microvasculature could potentially extend the therapeutic window in treating stroke by many hours.
Received November 10, 1999; revision received May 9, 2000; accepted May 9, 2000.
| References |
|---|
|
|
|---|
2.
Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY.
Polyethylene glycol-conjugated superoxide dismutase and catalase reduce
ischemic brain injury. Am J Physiol.. 1989;256:H589H93.
3. Moore PK, Babbedge RC, Wallace P, Gaffen ZA, Hart SL. 7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol.. 1993;108:296297.[Medline] [Order article via Infotrieve]
4. Betz LA. Identification for hypoxanthine transport and xanthine oxidase activity in brain capillaries. J Neurochem.. 1985;44:574579.[Medline] [Order article via Infotrieve]
5. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol.. 1996;9:836844.[Medline] [Order article via Infotrieve]
6. Sampson JB, Ye YZ, Rosen H, Beckman JS. Myeloperoxidase and horseradish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide. Arch Biochem Biophys.. 1998;356:207213.[Medline] [Order article via Infotrieve]
7.
MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS,
Thompson JA. Nitration and inactivation of manganese superoxide
dismutase in chronic rejection of human renal allografts. Proc
Natl Acad Sci U S A.. 1996;93:1185311858.
8. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry. 1998;37:16131622.[Medline] [Order article via Infotrieve]
9. Zou M-H, Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett.. 1996;382:101104.[Medline] [Order article via Infotrieve]
10. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem Hoppe Seyler. 1997;378:707713.
11. Zou MH, Klein T, Pasquet JP, Ullrich V. Interleukin 1beta decreases prostacyclin synthase activity in rat mesangial cells via endogenous peroxynitrite formation. Biochem J.. 1998;336:507512.
12. Viner RI, Ferrington DA, Williams TD, Bigelow DJ, Schöneich C. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2+-ATPase in skeletal muscle. Biochem J.. 1999;340:657669.
13. Viner RI, Ferrington DA, Hühmer AFR, Bigelow DJ, Schöneich C. Accumulation of nitrotyrosine on the SERCA2a isoform of SR Ca-ATPase of rat skeletal muscle during aging: a peroxynitrite-mediated process? FEBS Lett.,1996;379:286290.
14.
Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett
LJ. Peroxynitrite, the coupling product of nitric oxide and
superoxide, activates prostaglandin biosynthesis.
Proc Natl Acad Sci U S A. 1996;93:1506915074.
This article has been cited by other articles:
![]() |
H. Karatas, Y. Aktas, Y. Gursoy-Ozdemir, E. Bodur, M. Yemisci, S. Caban, A. Vural, O. Pinarbasli, Y. Capan, E. Fernandez-Megia, et al. A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood-Brain Barrier and Provides Neuroprotection J. Neurosci., November 4, 2009; 29(44): 13761 - 13769. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Reddy and V. Labhasetwar Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury FASEB J, May 1, 2009; 23(5): 1384 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Narasimhan, J. Liu, Y. S. Song, J. L. Massengale, and P. H. Chan VEGF Stimulates the ERK 1/2 Signaling Pathway and Apoptosis in Cerebral Endothelial Cells After Ischemic Conditions Stroke, April 1, 2009; 40(4): 1467 - 1473. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. T. Hare, A. K. Y. Tsui, A. T. McLaren, T. E. Ragoonanan, J. Yu, and C. D. Mazer Anemia and Cerebral Outcomes: Many Questions, Fewer Answers Anesth. Analg., October 1, 2008; 107(4): 1356 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, B. Jin, L. Li, E. R. Block, and J. M. Patel Nitric oxide-induced persistent inhibition and nitrosylation of active site cysteine residues of mitochondrial cytochrome-c oxidase in lung endothelial cells Am J Physiol Cell Physiol, April 1, 2005; 288(4): C840 - C849. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Muyderman, M. Nilsson, and N. R. Sims Highly Selective and Prolonged Depletion of Mitochondrial Glutathione in Astrocytes Markedly Increases Sensitivity to Peroxynitrite J. Neurosci., September 15, 2004; 24(37): 8019 - 8028. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Unal-Cevik, M. Kilinc, A. Can, Y. Gursoy-Ozdemir, and T. Dalkara Apoptotic and Necrotic Death Mechanisms Are Concomitantly Activated in the Same Cell After Cerebral Ischemia Stroke, September 1, 2004; 35(9): 2189 - 2194. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Fagan, D. C. Hess, E. J. Hohnadel, D. M. Pollock, and A. Ergul Targets for Vascular Protection After Acute Ischemic Stroke Stroke, September 1, 2004; 35(9): 2220 - 2225. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Iwashita, N. Tojo, S. Matsuura, S. Yamazaki, K. Kamijo, J. Ishida, H. Yamamoto, K. Hattori, N. Matsuoka, and S. Mutoh A Novel and Potent Poly(ADP-Ribose) Polymerase-1 Inhibitor, FR247304 (5-Chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), Attenuates Neuronal Damage in in Vitro and in Vivo Models of Cerebral Ischemia J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 425 - 436. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gursoy-Ozdemir, A. Can, and T. Dalkara Reperfusion-Induced Oxidative/Nitrative Injury to Neurovascular Unit After Focal Cerebral Ischemia Stroke, June 1, 2004; 35(6): 1449 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Maier, L. Hsieh, F. Yu, P. Bracci, and P. H. Chan Matrix Metalloproteinase-9 and Myeloperoxidase Expression: Quantitative Analysis by Antigen Immunohistochemistry in a Model of Transient Focal Cerebral Ischemia Stroke, May 1, 2004; 35(5): 1169 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ding-Zhou, C. Marchand-Verrecchia, B. Palmier, N. Croci, P.-E. Chabrier, M. Plotkine, and I. Margaill Neuroprotective Effects of (S)-N-[4-[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)carbonyl]-1-piperazinyl]phenyl]-2-thiophenecarboximid-amide (BN 80933), an Inhibitor of Neuronal Nitric-Oxide Synthase and an Antioxidant, in Model of Transient Focal Cerebral Ischemia in Mice J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 588 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Coert, R. E. Anderson, and F. B. Meyer Is neuroprotective efficacy of nNOS inhibitor 7-NI dependent on ischemic intracellular pH? Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H151 - H159. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Peeters-Scholte, J. Koster, W. Veldhuis, E. van den Tweel, C. Zhu, N. Kops, K. Blomgren, D. Bar, S. van Buul-Offers, H. Hagberg, et al. Neuroprotection by Selective Nitric Oxide Synthase Inhibition at 24 Hours After Perinatal Hypoxia-Ischemia Stroke, September 1, 2002; 33(9): 2304 - 2310. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Han, Y. Qiao, M. Karabiyikoglu, R. G. Giffard, and M. A. Yenari Influence of Mild Hypothermia on Inducible Nitric Oxide Synthase Expression and Reactive Nitrogen Production in Experimental Stroke and Inflammation J. Neurosci., May 15, 2002; 22(10): 3921 - 3928. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ozaki, S. Kawashima, T. Hirase, T. Yamashita, M. Namiki, N. Inoue, K.-i. Hirata, and M. Yokoyama Overexpression of Endothelial Nitric Oxide Synthase in Endothelial Cells Is Protective against Ischemia-Reperfusion Injury in Mouse Skeletal Muscle Am. J. Pathol., April 1, 2002; 160(4): 1335 - 1344. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |